Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Asia Pacific Prostate Cancer Conference /
Lecture: Exploring the androgen signalling pathway in CRPC

1st - 2nd Mar 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.05.14
Views: 2850

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

Dr Paul de Souza from New South Wales, Australia, discusses aspects of the androgen signalling pathway in castration resistant prostate cancer (CRPC), emphasising that androgen pathway signalling remains a major target for prostate cancer therapy due to its now-established role as a key driver in CRPC. He explains the androgen receptor structure and the complex signalling mechanism; also the changes to this in various stages of CRPC, eg, androgen receptor hypersensitivity and promiscuity, and bypass pathways. Dr de Souza explores how this target can be attacked with therapeutic androgen receptor blockers, such as abiraterone and enzalutamide, as well as newer agents, such as galeterone and HSP90.

This video is sponsored by an educational grant from Janssen Asia Pacific, a pharmaceutical company of Johnson & Johnson

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation